Lexeo Therapeutics Q1 net loss $20.2M; cash $227.6M; LX2006 pivotal trial protocol submitted to FDA

Lexeo Therapeutics, Inc.

2026-Q1 EPS reported -$0.25

Net loss $20.2M ($0.25/share) vs $32.7M ($0.99) in Q1 2025; R&D $15.7M, G&A $6.6M.
Cash, equivalents & investments $227.6M at March 31, 2026; expected runway into 2028.
LX2006 SUNRISE-FA2 pivotal protocol and SAP submitted to FDA; initiation expected Q2 2026.
Appointed Laura Sepp-Lorenzino, Ph.D., former CSO of Intellia, to Board of Directors.
ASGCT presentations: LX2006 shows significant mFARS improvement vs natural history (p=0.003); LX2022 preclinical data.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lexeo Therapeutics, Inc. reported the first quarter 2026 results: net income Net loss was $20.2 million or $0.25 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.25 per share (basic and diluted).

Period: the first quarter 2026
Net income: Net loss was $20.2 million or $0.25 per share (basic and diluted) for the three months ended March 31, 2026
EPS: $0.25 per share (basic and diluted)
Result: reported results

Exact text from the filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-215674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.